Free PSA measures the portion of prostate-specific antigen circulating unbound in the blood. Total PSA equals free PSA plus PSA bound to carrier proteins. The free-to-total ratio (%fPSA) adds specificity when total PSA sits in the gray zone of 4-10 ng/mL.
Free PSA's clinical value is almost entirely in the ratio with total PSA. A ratio above 25% suggests benign prostate conditions (BPH, prostatitis); a ratio below 10% raises concern for prostate cancer. Clinicians use this ratio to reduce unnecessary biopsies when total PSA is borderline. Tracking free PSA alone adds little. Pair it with total PSA to interpret.
Optimal PSA Free: 0-0.5 ng/mL.
Typically re-tested every 26 weeks.
The figure clinicians usually work with is percent free PSA, which is free PSA divided by total PSA. That ratio, not the raw free value, carries most of the interpretive weight.
PSA Free is the fraction of prostate-specific antigen in serum that is not bound to protease inhibitors, reported as a concentration in ng/mL.
Prostate-specific antigen is a serine protease produced by the epithelial cells lining the prostate ducts. It belongs to the kallikrein-related peptidase family, where it is also known as KLK3, and its normal job is in semen, where it thins the seminal coagulum after ejaculation[1]. Only a small amount escapes into the bloodstream, and the amount that escapes rises when prostate tissue is enlarged, inflamed, irritated or disorganised.
Once PSA reaches the blood, most of it is captured by circulating protease inhibitors, principally alpha-1-antichymotrypsin, and is reported as complexed PSA. A smaller portion stays unbound because it has already been inactivated or internally clipped, and that portion is what the lab measures as free PSA[2]. Total PSA is simply the sum of the bound and unbound forms.
Free PSA is not a single uniform molecule. It includes precursor forms such as proPSA and its truncated variants, which have been studied for their relationship to tumour stage and grade[3], and benign-associated forms that come mostly from the transition zone. Assays that measure specific subforms, such as the Prostate Health Index, combine total PSA, free PSA and a proPSA variant into a single risk score[4]. That is why two men with identical total PSA values can have very different free PSA fractions.
Related: Causes of High PSA (Beyond Prostate Cancer)
It matters because total PSA on its own is a blunt instrument, and the free fraction adds the specificity that total PSA lacks.
Total PSA rises for many reasons that have nothing to do with cancer. Benign enlargement, inflammation and recent prostate irritation all push it up, which means a single raised value frequently leads to anxiety and sometimes to a biopsy that returns nothing. Measuring the free fraction gives a clinician a second axis to read. Research suggests that a higher proportion of free PSA is more often associated with benign prostatic conditions, while a lower proportion in the presence of a raised total PSA is associated with a greater likelihood of cancer being found on biopsy[1].
This is most useful in the grey zone, where total PSA is mildly elevated but not dramatically so. It is also used in men who have already had a negative biopsy but whose PSA keeps climbing, a situation where percent free PSA and other kallikrein measures help a urologist decide whether to repeat sampling or to watch[5]. Multivariable models that fold free PSA into a risk calculation have been studied as a way to improve risk assessment compared with total PSA alone[4].
PSA measures also matter after treatment. When PSA rises again following prostatectomy, that biochemical signal is what prompts further imaging, and modern imaging has been shown to change how salvage radiotherapy is planned[6]. Over a lifetime, the value of this marker is less about any single reading and more about having a tracked baseline that makes a future change interpretable.
A typical laboratory reference range for serum free PSA sits at the low end of the scale, and FitScript sets a tighter optimisation target within it.
| Measure | Typical lab reference range | FitScript optimal range |
|---|---|---|
| PSA Free (serum) | 0 to 1 ng/mL | 0 to 0.5 ng/mL |
Free PSA rises with age. In 1,862 healthy Chinese men aged 21 to 94, the upper limit climbed from 0.60 ng/mL at 21 to 50 to 2.41 ng/mL at 81 and over.[13]
| Sex | Age | Upper limit, 95th percentile (ng/mL) |
|---|---|---|
| Men | 21 to 50 | Up to 0.60 |
| Men | 51 to 60 | Up to 0.76 |
| Men | 61 to 70 | Up to 0.83 |
| Men | 71 to 80 | Up to 1.30 |
| Men | 81 and over | Up to 2.41 |
The same study set a lower limit for the free to total PSA ratio of 0.16 at 21 to 50 and 0.13 at 51 and over.[13] These are limits in one population, not cancer cut-offs. A free PSA result is interpreted with a clinician alongside total PSA, age and prior results.
Reference ranges vary by laboratory, assay, age and sex, so always read your result against the range printed on your own report. The optimal range shown here is an optimisation target, not a diagnostic cut-off, and a value outside it is not a diagnosis of anything.
Two further points matter. First, no age-banded optimal range is published for this marker, and age-specific free PSA thresholds differ between assays, so any by-age figure you see elsewhere should be treated as assay-specific rather than universal. Second, the free value is rarely interpreted alone. Percent free PSA, calculated from free and total PSA on the same sample, is the derived figure clinicians use most, and the thresholds applied to it depend on the total PSA band and the assay the laboratory runs. Because PSA is a prostate protein, free PSA testing is interpreted in men and is not part of routine panels for women.
A free PSA value above the typical range usually travels with a raised total PSA, and most often reflects a prostate that is enlarged, inflamed or recently irritated rather than anything malignant.
Men with this pattern often report urinary symptoms. Common ones include needing to urinate more often, getting up at night, a weaker or slower stream, hesitancy, a sense of incomplete emptying, and sometimes pelvic, perineal or ejaculatory discomfort when inflammation is involved. Free PSA itself produces no symptoms. The symptoms come from whatever is going on in the gland.
Common contributors include benign prostatic hyperplasia, acute or chronic prostatitis, urinary tract infection, urinary retention, recent catheterisation or instrumentation, a recent biopsy, and prostatic calculi, which have been associated with measurable biochemical and symptomatic effects in men with prostate complaints[7]. Recent ejaculation and prolonged cycling can also nudge PSA measures upward.
The long-term picture depends on the ratio and the trend, not the single number. A raised total PSA accompanied by a generously high free fraction more often points toward benign enlargement, which is a quality-of-life and urinary-function issue over decades rather than a cancer concern. Still, a high result is worth discussing with a clinician, who will look at the trend, the percent free value, a physical examination and your symptoms together. Never ignore an abnormal result, and if a high value comes with fever, severe pain or an inability to pass urine, seek care promptly.
A low absolute free PSA usually just mirrors a low total PSA, which is an unremarkable finding in most men.
On its own, a small free PSA number causes no symptoms and signals nothing concerning. The pattern that carries meaning is a low free fraction relative to total PSA, meaning the percent free is low while total PSA is elevated. That combination is associated with a higher probability that a biopsy would find cancer, and it is one of the reasons the free measure is ordered alongside the total[1][5]. It is an association across populations, not a verdict about an individual, and only a urologist working with imaging and tissue can establish what is actually present.
Low values can also be medication-driven. Treatment with a 5-alpha reductase inhibitor changes the molecular forms of PSA in circulation and lowers measured values, which is why clinicians adjust their interpretation for men taking these drugs[8]. Androgen-directed therapies suppress PSA production markedly, an effect used deliberately in the neoadjuvant setting before prostate brachytherapy[9].
In terms of long-term impact, a persistently low percent free alongside a rising total PSA is the pattern that leads to specialist referral, imaging and possibly biopsy. If disease is confirmed, the options a specialist weighs range from active surveillance through radiotherapy to surgery, and even clinically locally advanced disease has been studied as a candidate for radical prostatectomy within a multimodal approach[10]. Those are decisions for a treating clinician, informed by far more than one blood marker.
Quite a lot, which is why single readings should be interpreted cautiously and repeat testing is often the first sensible step.
Activity and examination come first. Ejaculation in the days before the draw, vigorous or prolonged cycling, a digital rectal examination, catheterisation, cystoscopy and especially a recent prostate biopsy can all raise PSA measures. An active urinary tract infection or a flare of prostatitis can raise them substantially, and values are usually rechecked after the infection has settled rather than acted on during it.
Laboratory handling matters more for this marker than for most. The free fraction is the less stable of the two, so the time between the blood draw and processing, along with storage conditions, can influence the result, and different assays do not always produce interchangeable numbers[2]. Comparing a result from one laboratory against a result from another is a common source of false alarm. Track trends on the same assay where possible.
Medications are the other major factor. 5-alpha reductase inhibitors used for benign enlargement or hair loss alter the measured molecular forms of PSA[8], and androgen suppression lowers PSA production[9]. Testosterone therapy also influences prostate markers and requires monitoring, and a licensed provider evaluates whether any of these prescription treatments is appropriate for a given person. No dosing guidance belongs on a page like this.
The role of diet and supplements is not established. One small trial of dried cranberry in men with lower urinary tract symptoms reported changes in urinary symptom scores and PSA measures[11], and adjunctive herbal regimens have been examined alongside endocrine therapy in advanced disease[12]. None of this makes any supplement a treatment, and nothing here should be used in place of a clinician's assessment.
Free PSA is measured from a serum sample on the same draw as total PSA, because the two values are only useful together.
It sits within the male hormone and prostate section of the membership's bloodwork, part of a programme built around 150+ biomarkers tested per year, so the result arrives beside androgens, metabolic markers and inflammation rather than in isolation. That context matters, since several hormonal and medication factors influence what the prostate releases into circulation.
Atlas, FitScript's AI health advisor, reads the free and total values together, calculates the ratio, compares the result against your own previous draws and flags the direction of travel rather than fixating on a single point. The interpretation it writes becomes part of your FitScript, which is updated as new bloodwork arrives. Where a result sits outside the standard range, is drifting upward across draws, or is accompanied by urinary symptoms, the appropriate next step is a conversation with a clinician, and anything suggesting infection or acute retention is worth discussing with a clinician promptly. For any prescription option that touches prostate markers, including hormone therapy, a licensed provider evaluates whether it is appropriate after reviewing the full picture.
The free value is uninterpretable without total PSA, and the hormonal environment around the prostate explains a good deal of the rest.
Start with PSA, since the ratio between the two is the figure that carries the clinical meaning, then look at the androgen axis that drives prostate tissue, including Testosterone Total for overall production, Testosterone Free for the unbound portion available to tissue, SHBG because it governs how much of that testosterone stays bound, Dihydrotestosterone as the more potent androgen most directly implicated in prostate growth, and DHEA-S as a marker of adrenal androgen supply, all of which are typically drawn together on hormone lab panels, or the focused Prostate PSA panel so the picture can be read as one system rather than six separate numbers.
PSA Free is a small unbound fraction of a prostate protein, and its value lies almost entirely in the ratio it forms with total PSA. A higher free fraction leans benign, a lower one raises the question of further investigation, and both readings are shaped by recent activity, infection, medication and the laboratory itself. One result is a data point. A tracked series is information.
This article is educational and is not medical advice. Discuss your results and any treatment decisions with a clinician or licensed provider who can see your full history.
It means the portion of prostate-specific antigen in your blood that is not bound to protease inhibitors, reported in ng/mL. The rest of the PSA in circulation is complexed to carrier proteins. Free plus complexed equals total PSA, and the relationship between free and total is what a clinician reads.
A typical laboratory reference range for serum free PSA sits around 0 to 1 ng/mL, and FitScript's optimal range is 0 to 0.5 ng/mL as an optimisation target rather than a diagnostic cut-off. Ranges vary by laboratory, assay, age and sex, so read your result against the range printed on your own report.
Age-adjusted thresholds exist for total PSA in some guidance, but age bands for the free fraction differ between assays and laboratories, and no age-banded optimal range is published here. Rather than chasing an age figure, compare your result with your own previous draws on the same assay and with the range on your report.
No. A low free PSA most often simply reflects a low total PSA, which is unremarkable. The pattern that prompts further assessment is a low percentage of free PSA alongside an elevated total PSA, which is associated with a higher likelihood of finding cancer on biopsy. That is a population-level association, not a diagnosis, and only a urologist can establish what is present.
It is not a cancer test by itself. It is a refinement that helps interpret an elevated total PSA, improving the ability to separate benign causes from those needing further investigation. Diagnosis requires clinical assessment, imaging and tissue sampling decided on by a specialist.
Recent ejaculation, prolonged cycling, a digital rectal examination, catheterisation, cystoscopy and especially a recent prostate biopsy can all raise PSA measures. An active urinary infection or prostatitis flare can raise them substantially, and testing is usually repeated once the infection has settled.
Yes. 5-alpha reductase inhibitors used for benign prostate enlargement or hair loss alter the measured molecular forms of PSA and lower values, and androgen suppression reduces PSA production markedly. Testosterone therapy also influences prostate markers. Tell your clinician everything you take, and remember that a licensed provider decides whether any prescription treatment is appropriate.
Testing frequency depends on age, symptoms, family history and what previous results showed, so it is a decision to make with a clinician. Within a tracked membership, prostate markers are drawn alongside hormones and metabolic markers so trends can be followed over time rather than judged from a single reading.